Catalent (NYSE:CTLT) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a report published on Friday morning. The firm issued a sell rating on the stock.

Other equities research analysts have also issued research reports about the company. UBS Group restated a neutral rating and set a $63.50 target price (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Royal Bank of Canada reaffirmed a sector perform rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. Stephens reaffirmed an equal weight rating and set a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. Finally, Barclays upped their price target on Catalent from $45.00 to $47.00 and gave the stock an equal weight rating in a research note on Thursday, January 25th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of Hold and a consensus price target of $52.46.

Catalent Stock Down 0.6 %

Shares of Catalent stock opened at $55.48 on Friday. Catalent has a one year low of $31.45 and a one year high of $60.20. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The stock’s 50-day moving average is $56.81 and its 200 day moving average is $48.24. The firm has a market cap of $10.04 billion, a price-to-earnings ratio of -8.16, a PEG ratio of 6.04 and a beta of 1.20.

Catalent (NYSE:CTLT) last announced its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the company earned $0.62 EPS. The firm’s revenue for the quarter was down 10.2% on a year-over-year basis. Equities research analysts anticipate that Catalent will post 0.28 EPS for the current year.

Institutional Trading of Catalent

Institutional investors and hedge funds have recently modified their holdings of the business. KB Financial Partners LLC purchased a new stake in shares of Catalent during the first quarter valued at approximately $30,000. Covestor Ltd increased its position in shares of Catalent by 84.9% during the first quarter. Covestor Ltd now owns 562 shares of the company’s stock valued at $62,000 after acquiring an additional 258 shares during the last quarter. Gladius Capital Management LP purchased a new stake in shares of Catalent during the third quarter valued at approximately $28,000. Exchange Traded Concepts LLC purchased a new stake in shares of Catalent during the third quarter valued at approximately $31,000. Finally, GAMMA Investing LLC purchased a new stake in shares of Catalent during the fourth quarter valued at approximately $33,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.